Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nventa Biopharmaceuticals Corp.

Division of Akela Pharma Inc.
www.nventacorp.com

Latest From Nventa Biopharmaceuticals Corp.

Akela Pharma downsizes to conserve cash for fentanyl programme

In a bid to conserve cash, Canada's Akela Pharma is restructuring its operations and reducing its headcount by a third. It will close several of its international sites and centralise operations in Austin, Texas, home of its contract services subsidiary PharmaForm.

Cancer Neurology

Akela Pharma makes senior appointments

The US drug development company Akela Pharma has appointed Greg McKee president and CEO and Robert Rieder chairman; both appointments are effective immediately. Mr McKee currently serves on Akela's board of directors, which he will continue to do alongside his new roles. He previously served as president and CEO of Nventa Biopharmaceuticals – which merged with Akela earlier this year – and before that served as vice-president of corporate development and CFO at the company. He has also held roles at Valentis and Genzyme. Mr Rieder currently serves as executive chairman of the board of directors of Cardiome Pharma, where he previously held the role of CEO. He has also held several senior roles at MDS Ventures Pacific, DBA Telecom and Synapse Technologies.

Companies

Top Biotech Licensings of 2002

We review 2002's top ten highest value biotech alliances.
BioPharmaceutical

Can Heat Shock Proteins Improve Immunotherapy?

Therapeutic vaccines derived from antigenic peptides have yet to demonstrate significant efficacy, particularly in cancer. Over the past eight years, a series of observations has led a small group of companies to believe that heat shock proteins possess unique properties that could make them useful adjuvants in vaccines designed to generate specific immune responses against cancers and infectious agents.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Stressgen Biotechnologies Corp.
  • GVIC Publications Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Akela Pharma Inc.
  • Senior Management
  • Richard B Lai Fatt, PhD, VP, Corp. Dev.
    Peter Emtage, PhD, VP, R&D
    David Duncan, Jr., VP, Fin.
  • Contact Info
  • Nventa Biopharmaceuticals Corp.
    Phone: (858) 202-4900
    9381 Judicial Drive, Suite 180
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register